Non-alcoholic fatty liver disease and intestinal immune status: a narrative review

References

• Cotter TG, Rinella M. Nonalcoholic fatty liver disease 2020: the state of the disease. Gastroenterology. 2020;158(7):1851–1864.
   PubMed Web of Science ®Google Scholar
• Zhou J, Zhou F, Wang W, et al. Epidemiological features of NAFLD from 1999 to 2018 in China. Hepatology. 2020;71(5):1851–1864.
   PubMed Web of Science ®Google Scholar
• Katsiki N, Perez-Martinez P, Anagnostis P, et al. Is nonalcoholic fatty liver disease indeed the hepatic manifestation of metabolic syndrome? Curr Vasc Pharmacol. 2018;16(3):219–227.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Csermely A, Petracca G, et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(11):903–913.
   PubMed Web of Science ®Google Scholar
• Schoeler M, Caesar R. Dietary lipids, gut microbiota and lipid metabolism. Rev Endocr Metab Disord. 2019;20(4):461–472.
   PubMed Web of Science ®Google Scholar
• Zeng Y, Luo M, Pan L, et al. Vitamin D signaling maintains intestinal innate immunity and gut microbiota: potential intervention for metabolic syndrome and NAFLD. Am J Physiol Gastrointest Liver Physiol. 2020;318(3):G542–G553.
   PubMed Web of Science ®Google Scholar
• Luci C, Vieira E, Perchet T, et al. Natural killer cells and type 1 innate lymphoid cells are new actors in non-alcoholic fatty liver disease. Front Immunol. 2019;10:1192.
   PubMed Web of Science ®Google Scholar
• Su L, Wu Z, Chi Y, et al. Mesenteric lymph node CD4+ T lymphocytes migrate to liver and contribute to non-alcoholic fatty liver disease . Cell Immunol. 2019;337:33–41.
   PubMed Web of Science ®Google Scholar
• VAN Zutphen T, Bertolini A, DE Vries HD, et al. Potential of Intestine-Selective FXR modulation for treatment of metabolic disease. Handb Exp Pharmacol. 2019;256:207–234.
   PubMedGoogle Scholar
• Gross-Vered M, Trzebanski S, Shemer A, et al. Defining murine monocyte differentiation into colonic and ileal macrophages. Elife. 2020; 9:9.
   Web of Science ®Google Scholar
• Man AL, Gicheva N, Regoli M, et al. CX3CR1+ cell-mediated salmonella exclusion protects the intestinal mucosa during the initial stage of infection. J Immunol. 2017;198(1):335–343.
   PubMed Web of Science ®Google Scholar
• Tsujimoto T, Kawaratani H, Kitazawa T, et al. Innate immune reactivity of the ileum-liver axis in nonalcoholic steatohepatitis. Dig Dis Sci. 2012;57(5):1144–1151.
   PubMed Web of Science ®Google Scholar
• Imajo K, Fujita K, Yoneda M, et al. Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic steatohepatitis is regulated by leptin-mediated signaling. Cell Metab. 2012;16(1):44–54.
   PubMed Web of Science ®Google Scholar
• Isaacs-TEN A, Echeandia M, Moreno-Gonzalez M, et al. Intestinal microbiome-macrophage crosstalk contributes to cholestatic liver disease by promoting intestinal permeability in mice. Hepatology. 2020;72(6):2090–2108.
   PubMed Web of Science ®Google Scholar
• Scott NA, Andrusaite A, Andersen P, et al. Antibiotics induce sustained dysregulation of intestinal T cell immunity by perturbing macrophage homeostasis. Sci Transl Med. 2018;10(464):eaao4755.
   Web of Science ®Google Scholar
• Fernando MR, Saxena A, Reyes JL, et al. Butyrate enhances antibacterial effects while suppressing other features of alternative activation in IL-4-induced macrophages. Am J Physiol Gastrointest Liver Physiol. 2016;310(10):G822–831.
   PubMed Web of Science ®Google Scholar
• Schulthess J, Pandey S, Capitani M, et al. The short chain fatty acid butyrate imprints an antimicrobial program in macrophages. Immunity. 2019;50(2):432–445.e437.
   PubMed Web of Science ®Google Scholar
• Deng M, Qu F, Chen L, et al. SCFAs alleviated steatosis and inflammation in mice with NASH induced by MCD. J Endocrinol. 2020;245(3):425–437.
   PubMed Web of Science ®Google Scholar
• Hua Y, Yang Y, Sun S, et al. Gut homeostasis and regulatory T cell induction depend on molecular chaperone gp96 in CD11c + cells(+). Sci Rep. 2017;7(1):2171.
   PubMedGoogle Scholar
• Steimle A, Frick JS. Molecular mechanisms of induction of tolerant and tolerogenic intestinal dendritic cells in mice. J Immunol Res. 2016;2016:1958650.
   PubMed Web of Science ®Google Scholar
• Tacke F, Yoneyama H. From NAFLD to NASH to fibrosis to HCC: role of dendritic cell populations in the liver. Hepatology. 2013;58(2):494–496.
   PubMed Web of Science ®Google Scholar
• Almeda-Valdes P, Aguilar Olivos NE, Barranco-Fragoso B, et al. The role of dendritic cells in fibrosis progression in nonalcoholic fatty liver disease. Biomed Res Int. 2015;2015:768071.
   PubMed Web of Science ®Google Scholar
• Heier EC, Meier A, Julich-Haertel H, et al. Murine CD103+ dendritic cells protect against steatosis progression towards steatohepatitis. J Hepatol. 2017;66(6):1241–1250.
   PubMed Web of Science ®Google Scholar
• Henning JR, Graffeo CS, Rehman A, et al. Dendritic cells limit fibroinflammatory injury in nonalcoholic steatohepatitis in mice. Hepatology. 2013;58(2):589–602.
   PubMed Web of Science ®Google Scholar
• Fang JH, Yu W, Zhou G, et al. [Study on the correlation between small intestinal dendritic cells and non-alcoholic fatty liver disease in mice]. Zhonghua Gan Zang Bing Za Zhi. 2019;27(9):698–703.
   PubMedGoogle Scholar
• Mao JW, Tang HY, Zhao T, et al. Intestinal mucosal barrier dysfunction participates in the progress of nonalcoholic fatty liver disease. Int J Clin Exp Pathol. 2015;8(4):3648–3658.
   PubMed Web of Science ®Google Scholar
• Gao W, Wang Y, Bi J, et al. Impaired CCR9/CCL25 signalling induced by inefficient dendritic cells contributes to intestinal immune imbalance in nonalcoholic steatohepatitis. Biochem Biophys Res Commun. 2021;534:34–40.
   PubMed Web of Science ®Google Scholar
• Hundertmark J, Krenkel O, Tacke F. Adapted immune responses of myeloid-derived cells in fatty liver disease. Front Immunol. 2018;9:2418.
   PubMed Web of Science ®Google Scholar
• Fung TC, Bessman NJ, Hepworth MR, et al. Lymphoid-tissue-resident commensal bacteria promote members of the IL-10 cytokine family to establish mutualism. Immunity. 2016;44(3):634–646.
   PubMed Web of Science ®Google Scholar
• Millard AL, Mertes PM, Ittelet D, et al. Butyrate affects differentiation, maturation and function of human monocyte-derived dendritic cells and macrophages. Clin Exp Immunol. 2002;130(2):245–255.
   PubMed Web of Science ®Google Scholar
• Liu L, Li L, Min J, et al. Butyrate interferes with the differentiation and function of human monocyte-derived dendritic cells. Cell Immunol. 2012;277(1–2):66–73.
   PubMed Web of Science ®Google Scholar
• Vavassori P, Mencarelli A, Renga B, et al. The bile acid receptor FXR is a modulator of intestinal innate immunity. J Immunol. 2009;183(10):6251–6261.
   PubMed Web of Science ®Google Scholar
• Geremia A, Arancibia-Carcamo CV. Innate lymphoid cells in intestinal inflammation. Front Immunol. 2017;8:1296.
   PubMed Web of Science ®Google Scholar
• Sivori S, Pende D, Quatrini L, et al. NK cells and ILCs in tumor immunotherapy. Mol Aspects Med. 2021;80:100870.
   PubMed Web of Science ®Google Scholar
• Tan S, Xu Y, Wang Z, et al. Tim-3 hampers tumor surveillance of liver-resident and conventional NK cells by disrupting PI3K signaling. Cancer Res. 2020;80(5):1130–1142.
   PubMed Web of Science ®Google Scholar
• Tosello-Trampont AC, Krueger P, Narayanan S, et al. NKp46(+) natural killer cells attenuate metabolism-induced hepatic fibrosis by regulating macrophage activation in mice. Hepatology. 2016;63(3):799–812.
   PubMed Web of Science ®Google Scholar
• Fan Y, Zhang W, Wei H, et al. Hepatic NK cells attenuate fibrosis progression of non-alcoholic steatohepatitis in dependent of CXCL10-mediated recruitment. Liver Int. 2020;40(3):598–608.
   PubMed Web of Science ®Google Scholar
• Reynders A, Yessaad N, Vu Manh TP, et al. Identity, regulation and in vivo function of gut NKp46 + RORγt + and NKp46 + RORγt- lymphoid cells. Embo J. 2011;30(14):2934–2947.
   PubMed Web of Science ®Google Scholar
• Forkel M, Berglin L, Kekalainen E, et al. Composition and functionality of the intrahepatic innate lymphoid cell-compartment in human nonfibrotic and fibrotic livers. Eur J Immunol. 2017;47(8):1280–1294.
   PubMed Web of Science ®Google Scholar
• Wang S, Li J, Wu S, et al. Type 3 innate lymphoid cell: a new player in liver fibrosis progression. Clin Sci (Lond)). 2018;132(24):2565–2582.
   PubMed Web of Science ®Google Scholar
• Wang Q, Li D, Zhu J, et al. Perforin acts as an immune regulator to prevent the progression of NAFLD. Front Immunol. 2020;11:846.
   PubMed Web of Science ®Google Scholar
• Su L, Wang JH, Cong X, et al. Intestinal immune barrier integrity in rats with nonalcoholic hepatic steatosis and steatohepatitis. Chin Med J. 2012;125(2):306–311.
   PubMed Web of Science ®Google Scholar
• Kim CS, Lee SC, Kim YM, et al. Visceral fat accumulation induced by a high-fat diet causes the atrophy of mesenteric lymph nodes in obese mice. Obesity. 2008;16(6):1261–1269.
   PubMed Web of Science ®Google Scholar
• Jiang W, Wu N, Wang X, et al. Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease. Sci Rep. 2015;5:8096.
   PubMed Web of Science ®Google Scholar
• Arpaia N, Campbell C, Fan X, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature. 2013;504(7480):451–455.
   PubMed Web of Science ®Google Scholar
• Carpino G, DEL Ben M, Pastori D, et al. Increased liver localization of lipopolysaccharides in human and experimental NAFLD. Hepatology. 2020;72(2):470–485.
   PubMed Web of Science ®Google Scholar
• Wang X, Ji D, Zhu B, et al. Contribution of endotoxin to Th17 bias in patients with non-alcoholic steatohepatitis. Microb Pathog. 2020;142:104009.
   PubMed Web of Science ®Google Scholar
• Hu Y, Zhang H, Li J, et al. Gut-derived lymphocyte recruitment to liver and induce liver injury in non-alcoholic fatty liver disease mouse model. J Gastroenterol Hepatol. 2016;31(3):676–684.
   PubMed Web of Science ®Google Scholar
• Kunisawa J. Metabolic changes during B cell differentiation for the production of intestinal IgA antibody. Cell Mol Life Sci. 2017;74(8):1503–1509.
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu J, Burrows PD, et al. B cell development and maturation. Adv Exp Med Biol. 2020;1254:1–22.
   PubMed Web of Science ®Google Scholar
• Bruzzi S, Sutti S, Giudici G, et al. B2-Lymphocyte responses to oxidative stress-derived antigens contribute to the evolution of nonalcoholic fatty liver disease (NAFLD). Free Radic Biol Med. 2018;124:249–259.
   PubMed Web of Science ®Google Scholar
• Moro-Sibilot L, Blanc P, Taillardet M, et al. Mouse and human liver contain immunoglobulin A-secreting cells originating from Peyer's patches and directed against intestinal antigens. Gastroenterology. 2016;151(2):311–323.
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Ichimura M, Tsuneyama K, et al. Fructo-oligosaccharides and intestinal barrier function in a methionine-choline-deficient mouse model of nonalcoholic steatohepatitis. PLOS One. 2017;12(6):e0175406.
   PubMed Web of Science ®Google Scholar
• Li S, Wu WC, He CY, et al. Change of intestinal mucosa barrier function in the progress of non-alcoholic steatohepatitis in rats. World J Gastroenterol. 2008;14(20):3254–3258.
   PubMed Web of Science ®Google Scholar
• Mcpherson S, Henderson E, Burt AD, et al. Serum immunoglobulin levels predict fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol. 2014;60(5):1055–1062.
   PubMed Web of Science ®Google Scholar
• Catanzaro JR, Strauss JD, Bielecka A, et al. IgA-deficient humans exhibit gut microbiota dysbiosis despite secretion of compensatory IgM. Sci Rep. 2019;9(1):13574.
   PubMedGoogle Scholar
• Mirpuri J, Raetz M, Sturge CR, et al. Proteobacteria-specific IgA regulates maturation of the intestinal microbiota. Gut Microbes. 2014;5(1):28–39.
   PubMed Web of Science ®Google Scholar
• Moon C, Baldridge MT, Wallace MA, et al. Vertically transmitted faecal IgA levels determine extra-chromosomal phenotypic variation. Nature. 2015;521(7550):90–93.
   PubMed Web of Science ®Google Scholar
• Isobe J, Maeda S, Obata Y, et al. Commensal-bacteria-derived butyrate promotes the T-cell-independent IgA response in the colon. Int Immunol. 2020;32(4):243–258.
   PubMed Web of Science ®Google Scholar
• Kim M, Qie Y, Park J, et al. Gut microbial metabolites fuel host antibody responses. Cell Host Microbe. 2016;20(2):202–214.
   PubMed Web of Science ®Google Scholar
• Ilan Y, Shailubhai K, Sanyal A. Immunotherapy with oral administration of humanized anti-CD3 monoclonal antibody: a novel gut-immune system-based therapy for metaflammation and NASH. Clin Exp Immunol. 2018;193(3):275–283.
   PubMed Web of Science ®Google Scholar
• Ilan Y, Gingis-Velitski S, Ben Ya'Aco A, et al. A plant cell-expressed recombinant anti-TNF fusion protein is biologically active in the gut and alleviates immune-mediated hepatitis and colitis. Immunobiology. 2017;222(3):544–551.
   PubMed Web of Science ®Google Scholar
• Ilan Y, Ben Ya'Acov A, Shabbat Y, et al. Oral administration of a non-absorbable plant cell-expressed recombinant anti-TNF fusion protein induces immunomodulatory effects and alleviates nonalcoholic steatohepatitis. World J Gastroenterol. 2016;22(39):8760–8769.
   PubMed Web of Science ®Google Scholar
• Lalazar G, Mizrahi M, Turgeman I, et al. Oral administration of OKT3 MAb to patients with NASH, promotes regulatory T-cell induction, and alleviates insulin resistance: results of a phase IIa blinded placebo-controlled trial. J Clin Immunol. 2015;35(4):399–407.
   PubMed Web of Science ®Google Scholar
• Weiner HL, DA Cunha AP, Quintana F, et al. Oral tolerance. Immunol Rev. 2011;241(1):241–259.
   PubMedGoogle Scholar
• Almon E, Khoury T, Drori A, et al. An oral administration of a recombinant anti-TNF fusion protein is biologically active in the gut promoting regulatory T cells: Results of a phase I clinical trial using a novel oral anti-TNF alpha-based therapy. J Immunol Methods. 2017;446:21–29.
   PubMed Web of Science ®Google Scholar
• Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385(9972):956–965.
   PubMed Web of Science ®Google Scholar
• Albillos A, DE Gottardi A, Rescigno M. The gut-liver axis in liver disease: pathophysiological basis for therapy. J Hepatol. 2020;72(3):558–577.
   PubMed Web of Science ®Google Scholar
• Gao J, Li Y, Wan Y, et al. A novel postbiotic from Lactobacillus rhamnosus GG with a beneficial effect on intestinal barrier function. Front Microbiol. 2019;10:477.
   PubMed Web of Science ®Google Scholar
• Compare D, Rocco A, Coccoli P, et al. Lactobacillus casei DG and its postbiotic reduce the inflammatory mucosal response: an ex-vivo organ culture model of post-infectious irritable bowel syndrome. BMC Gastroenterol. 2017;17(1):53.
   PubMedGoogle Scholar
• Chen J, Vitetta L. Gut microbiota metabolites in NAFLD pathogenesis and therapeutic implications. Int J Mol Sci. 2020;21(15):5214.
   Web of Science ®Google Scholar
• Manolis AA, Manolis TA, Melita H, et al. Gut microbiota and cardiovascular disease: Symbiosis versus dysbiosis. Curr Med Chem. 2021. DOI:https://doi.org/10.2174/0929867328666211213112949
   Google Scholar